Edwards Lifesciences Corporation (NYSE:EW) had its price objective hoisted by Barclays PLC from $108.00 to $120.00 in a research report released on Thursday morning. Barclays PLC currently has an equal weight rating on the medical research company’s stock.
Other equities research analysts have also issued reports about the stock. Jefferies Group LLC restated a buy rating on shares of Edwards Lifesciences Corporation in a research report on Wednesday, April 26th. Vetr lowered shares of Edwards Lifesciences Corporation from a strong-buy rating to a buy rating and set a $124.67 target price on the stock. in a research report on Monday, May 15th. Royal Bank Of Canada restated a buy rating on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 30th. Bank of America Corporation boosted their target price on shares of Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the stock a buy rating in a research report on Tuesday, May 30th. Finally, Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a hold rating to a buy rating and set a $125.00 target price on the stock in a research report on Monday, May 22nd. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $120.89.
Edwards Lifesciences Corporation (EW) traded down 0.73% during trading on Thursday, reaching $115.51. 2,185,053 shares of the company’s stock traded hands. The stock has a market cap of $24.31 billion, a P/E ratio of 35.03 and a beta of 0.64. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The firm’s 50 day moving average price is $117.23 and its 200-day moving average price is $104.08.
Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences Corporation (NYSE:EW) Price Target Raised to $120.00 at Barclays PLC” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/29/edwards-lifesciences-corporation-nyseew-price-target-raised-to-120-00-at-barclays-plc.html.
In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total value of $3,883,845.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 184,951 shares of company stock valued at $20,780,242. Corporate insiders own 2.13% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Sabal Trust CO boosted its position in Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the period. Alexandria Capital LLC boosted its position in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. Quadrant Capital Group LLC boosted its position in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the period. Rehmann Capital Advisory Group boosted its position in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock valued at $319,000 after buying an additional 55 shares during the period. Finally, M Holdings Securities Inc. boosted its position in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 62 shares during the period. 83.96% of the stock is owned by institutional investors.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
